GleamWall
中文EN

TSHA Taysha Gene Therapies, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1806310 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-13.1%
TTM net income YoY-56.1%
TTM EPS YoY-27.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,935.4%
Net margin-2,844.6%
FCF margin-2,582.6%
EBITDA margin-2,913.6%

Returns

ROE-54.2%
ROA-41.5%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets17.9%
Debt / equity0.13x
Current ratio18.56x
Interest coverage-5,193.77x

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue13.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$5.49M$0$1.99M$2.30M$2.02M
R&D expense$28.77M$38.64M$33.81M$24.95M$25.75M$20.14M$15.56M$15.32M
SG&A expense$13.11M$12.15M$9.68M$8.83M$8.28M$8.60M$8.16M$6.63M
Operating income-$41.87M-$47.35M-$43.49M-$28.30M-$34.02M-$26.75M-$21.42M-$19.93M
Interest expense$4,000$6,000$9,000$12,000$15,000$17,000$19,000$22,000
Income tax$0$0$0$0$0$0$0$0
Net income-$39.13M-$46.64M-$42.41M-$27.85M-$32.73M-$26.88M-$21.53M-$18.79M
EBITDA-$41.67M-$46.95M-$43.19M-$28.00M-$33.82M-$26.45M-$21.14M-$19.63M
EPS (basic)-0.10-0.13-0.12—-0.09-0.09-0.08—
EPS (diluted)-0.10-0.13-0.12—-0.09-0.09-0.08—
Weighted avg. shares (diluted)406.11M369.04M366.63M—353.31M297.99M269.31M—
Balance sheet
Cash & equivalents$422.83M$455.41M$276.58M$319.77M$297.34M$312.76M$116.59M$139.04M
Current assets$426.06M$461.43M$282.25M$324.65M$299.95M$316.26M$120.71M$142.13M
PP&E, net$2.53M$2.41M$6.45M$6.74M$6.80M$6.96M$7.24M$7.49M
Total assets$435.03M$470.43M$300.35M$343.32M$316.55M$333.33M$138.36M$160.36M
Current liabilities$22.95M$25.98M$20.10M$26.55M$28.63M$25.35M$22.56M$26.23M
Long-term debt$47.33M$49.26M$48.96M$50.11M$50.85M$41.05M$42.45M$43.94M
Total debt$47.33M$49.26M$48.96M$50.11M$50.85M$41.05M$42.45M$43.94M
Total liabilities$78.06M$83.17M$88.41M$96.38M$97.56M$84.60M$83.30M$88.84M
Shareholders' equity$356.97M$387.27M$211.94M$246.94M$218.99M$248.73M$55.06M$71.53M
Net debt-$375.50M-$406.15M-$227.62M-$269.66M-$246.49M-$271.71M-$74.14M-$95.09M
Shares outstanding325.88M325.30M287.28M285.05M273.92M272.73M205.05M204.94M
Cash flow statement
Operating cash flow-$32.91M-$40.42M-$40.88M-$26.72M-$24.17M-$20.18M-$22.02M-$18.31M
Capital expenditure$443,000-$1,000$24,000$250,000$108,000$2,000$378,000-$2,000
Free cash flow-$33.36M-$40.42M-$40.90M-$26.97M-$24.27M-$20.18M-$22.40M-$18.31M
Investing cash flow-$443,000$1,000-$3.02M-$247,000-$48,000$62,000-$371,000$13,000
Financing cash flow$785,000$216.66M$711,000$49.56M$8.80M$216.29M-$52,000-$357,000
Depreciation & amortization$200,000$400,000$295,000$299,000$200,000$300,000$283,000$304,000
Stock-based compensation$6.08M$5.81M$5.55M$3.53M$3.29M$3.19M$3.29M$3.22M

Free plan shows the latest 8 periods; Pro shows all 28 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.